Newsletter - Banner


Asset Publisher

angle-left Hope on the horizon for hard-to-treat breast cancers

Unique multi-party collaboration forged to develop new anti-cancer therapies targeting DNA repair regulators

May 17, 2019

Alain Nepveu, PhD, is a member of the Cancer Research Program at the Research Institute of the MUHCSource: Neomed. The NEOMED Institute (NEOMED), CQDM, the Canadian Cancer Society (CCS), the Goodman Cancer Research Centre (GCRC) and the Lady Davis Institute (LDI) announced today a unique multi-party collaboration to develop new anti-cancer therapies.

This collaboration is intended to more rapidly advance two novel research programs – based on two key regulators of DNA repair mechanisms, namely CUX1 and PARG – that are considered important new targets involved in hard-to-treat breast cancers including aggressive breast cancer sub-types. Both programs will be advanced at the NEOMED Institute and in the laboratories of Alain Nepveu, PhD, at McGill University’s Goodman Cancer Research Centre and the Research Institute of the McGill University Health Centre (CUX1) and Michael Witcher, PhD, at the Lady Davis Institute of the Jewish General Hospital (PARG). 

Learn more